Next Phase Newsletter

A newly established venture capital firm based in the USA has just successfully closed the first round of their fund ($20M target), and made its first investment. The firm invests globally in medically related early-stage companies. Initial size of investment ranges from $250 – 500K. While the firm is focused on USA-based companies, the firm is open to considering companies across the globe.

The firm invests in medtech and digital health companies. While the founder has decades of experience as an oculofacial plastic surgeon, the firm is generally opportunistic and will consider any promising technologies that address unmet medical need. The firm has looked at AI companies, digital health/software companies implementable in medical practices, etc. In terms of stage of development, the firm is open to investing as early as pre-prototype, given that the company has properly researched the idea behind their technology.

The firm has no specific company or management team requirements, and is open to acting as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com

The firm is a global chemical company founded in 1935. A subsidiary was initially established as the firm’s first U.S. representative office in NY in 1964 and has grown to become the corporation’s main sales, marketing, and business development center in North America. In addition to a variety of other markets, the firm serves the chemical, petrochemical and bioscience markets. The firm has recently started a corporate venture initiative with a $300M budget to make strategic investments into both pre and post-commercial companies. The group is flexible in terms of structuring investments and may employ equity investments, M&A and licensing agreements. The firm targets investment sizes from $100k – $5M for early stage companies and $10M-$50M for commercial-stage companies.

In terms of the healthcare and life science sectors, the firm is most interested in companies working in diagnostics and research tools. The firm is particularly interested in clinical diagnostics including IVDs and next generation platforms (NGS, liquid biopsy, LC-MS, point-of-care testing, digital PCR), separation media and connected devices and wearable medical sensors. The group is also interested in advanced materials including materials for secondary batteries, thin-film for electronic devices, separation (inorganic/organic/polymers) and composites. The firm is agnostic to indication area, but has a particular interest in cancer, metabolic (including diabetes) and kidney disorders as well as reproductive health.

The firm has no strict company or management team requirements and invest in both early and later stage opportunities. Board observer status is required along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is the corporate venture arm of an insurance company and is based in the Midwest. The firm was founded in 2016 and since then has made 30 investments. One of the firm’s main focus areas is in the longevity space as well as long term care. Within this space, the firm is open to all four sectors. The firm currently has a $350M fund and focuses mainly on Series A and B rounds in the form of equity, but will occasionally look at Seed rounds or late-stage rounds as well on a case by case basis. The firm is open to global opportunities, with a focus in US and Israeli markets.

The firm focuses on longevity investments and are open to all four life science sectors within that space. The firm looks for companies that have healthcare platforms that relate to monitoring and managing chronic conditions, as well as long term care and care coordination platforms. The firm is also interested in fintech companies focused on the retirement space as well as health data companies where the firm can find sources of data for life insurance and underwriting services. The firm will invest in all 3 classes of medical devices. The firm is not interested in biomedical companies and they do not invest in pre-clinical or pre-prototype companies.

The firm is open to all types of management teams from any type of background. The firm does not lead investments and prefers to co-invest

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The venture fund is an early stage investor in emerging life science technologies that was founded in 2003 and is based in Washington, with additional offices in New York City and San Diego. The firm closed its fourth fund in 2015 at $62.8 million. The firm seeks to invest in promising early-stage assets, create a company around each asset and then directly manage the startup. The firm’s investment sizes vary from $1-40 million. Investments are made at the seed stage or in Series A venture rounds; the firm prefers to be the first institutional investor. The firm has invested in assets sourced throughout the USA and has evaluated investment opportunities globally.

The firm primarily invests in therapeutics-focused opportunities. The firm is technologically agnostic and is open to any indication area, with a particular interest in CNS, digital health, oncology and immunology. The firm is interested in preclinical-stage assets and will consider investing in assets as early as the discovery stage.

The firm is open to working with both academic projects and entrepreneurs, and also deprioritized pharma assets. The firm generally does not make new investments into companies any later than the Series A stage. The firm supplies management and technical expertise to develop an asset if the company does not have a full management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Founded in 2019, a China-based firm sponsored by the local municipal government manages 2 funds that associated with their local incubator: one USD fund of $100MM and one RMB fund of $1,000MM, and is open to global in-licensing opportunities.

The firm focuses on Class II and Class III medical devices at the development stage, especially prototype-ready projects. The firm pays special attention to companies that are developing projects related to stroke, cardiovascular disease, eye disease, and medical robots. Currently, the firm is not interested in the IVD sector.

The firm prefers companies with a Chinese angle and are open to discussing China rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture arm of a pharmaceutical company is looking to make investments around $3 million in companies in the life science space. The firm could make as many as 2-3 investment over the next year and is willing to allocate to companies located around the globe. Besides equity investment, the firm would consider local licensing opportunities.

The firm is currently looking for companies developing therapeutics and is open to small molecules, biologics, and cell/gene therapy. The team is more interested in companies working with single assets although they can consider platform technologies. Indications of interest include Oncology, Inflammation, Orphan diseases, Critical care, Ophthalmology and Autoimmune diseases. The firm tends to be agnostic though and in spite of these focuses, is willing to look at most projects. The team looks for companies that have at least reached in-vivo proof of concept with their lead asset.

The firm looking for privately held companies and prefers companies with experienced management teams in place. The team looks to act as a value-added investor through their strategic alignment with their parent company, and looks to take a seat on the company’s board on a case by case basis. The firm is willing to both lead and co-invest in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA  has two funds under management and is currently investing out of its second fund. The firm seeks to make equity investments into life science companies from early to late stages. The typical investment size ranges from $2 million to $4 million. The firm plans to invest in 2-3 companies over the next 12 months and prefers to invest in companies based in US or Canada.

The firm is currently looking for new investment opportunities in life sciences.  The firm is primarily focused on clinical stage biotech opportunities, and will consider any indication area.  The firm prefers to invest in platform technologies rather than single asset companies.

The firm generally seeks to invest in private companies. The firm has no specific requirements for the company’s management team, and sometimes takes a board seat when investing.  For therapeutics, Excel looks for companies that are developing platform technologies but have a clear plan on moving the lead program forward.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.